Clinical Trials
45 trialsMK-3475-01E
Merck Sharp & Dohme LLC
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
MK-3475-01C
Merck Sharp & Dohme LLC
LEAP-005
Merck Sharp & Dohme LLC
INTerpath-012
Merck Sharp & Dohme LLC
MK-1308A-008
Merck Sharp & Dohme LLC
MK-4280A-010
Merck Sharp & Dohme LLC
KEYLYNK-009
Merck Sharp & Dohme LLC
MK-3475A-E39
Merck Sharp & Dohme LLC
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
University of California, San Diego
MK-4280A-008
Merck Sharp & Dohme LLC
LEAP-009
Merck Sharp & Dohme LLC
KEYNOTE-B61
Merck Sharp & Dohme LLC
MK-3475-01B
Merck Sharp & Dohme LLC
MK-1454-002
Merck Sharp & Dohme LLC
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
University of California, San Diego
KEYNOTE 158
Merck Sharp & Dohme LLC
INTerpath-004
Merck Sharp & Dohme LLC
Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)
Incyte Corporation
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)
Merck Sharp & Dohme LLC
KEYVIBE-005
Merck Sharp & Dohme LLC
KEYNOTE-B99
Merck Sharp & Dohme LLC
MK-3475-495
Merck Sharp & Dohme LLC
KEYNOTE-799
Merck Sharp & Dohme LLC
KEYNOTE-199
Merck Sharp & Dohme LLC
MK-7690-046
Merck Sharp & Dohme LLC
KEYNOTE-224
Merck Sharp & Dohme LLC
MK-3475-629
Merck Sharp & Dohme LLC
KEYNOTE-782
Merck Sharp & Dohme LLC
V937-011
Merck Sharp & Dohme LLC
KEYNOTE-164
Merck Sharp & Dohme LLC
MK-3475-170
Merck Sharp & Dohme LLC
HYPERION
Fudan University
MK-3475-427
Merck Sharp & Dohme LLC
MK-3475-052
Merck Sharp & Dohme LLC
Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma
Peking University
KEYNOTE-180
Merck Sharp & Dohme LLC
KEYNOTE-059
Merck Sharp & Dohme LLC
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Merck Sharp & Dohme LLC
Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
Portland VA Medical Center
KEYNOTE-100
Merck Sharp & Dohme LLC
Pembro/Carbo/Taxol in Endometrial Cancer
Big Ten Cancer Research Consortium
A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
Incyte Corporation
Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)
Merck Sharp & Dohme LLC
KEYNOTE 002
Merck Sharp & Dohme LLC